THRB and metabolic dysfunction-associated steatohepatitis: Recognition of this pathophysiological mechanism has contributed to the USA Food and Drug Administration’s approval of resmetirom, a liver-directed thyroid hormone receptor-beta (THR-β) agonist, for the treatment of adult non-cirrhotic MASH with moderate to advanced fibrosis (32).